The team’s projects focuses on triple-negative breast cancer (TNBC) for which effective treatments are crucially needed. In our integrated and multidisciplinary research, we want (i) to determine how the TNBC microenvironment is affected by proteases and the released bioactive fragments using N-TAILS proteomics (basic research axis); (ii) to target these extracellular/membrane proteins with proprietary antibodies as monotherapy, antibody-drug conjugates or combinations (translational axis); and (iii) to select TNBC subgroups for targeted and/or combined treatment with our proprietary antibodies (pre-clinical axis). Our ultimate objective is to translate our discoveries into clinical applications for the management of patients with specific TNBC subtypes in a personalized medicine approach.
Team Leader : Emmanuelle Liaudet-Coopman Institut de Recherche en 34298 Montpellier cedex 5 Tél. 33 (0)4 67 61 24 23 |
|